Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition

Peng, Tao‐Chun; Wu, Liwei; Chen, Wei‐Liang; Liaw, Fang‐Yih; Chang, Yaotsu; Kao, Tung‐Wei

doi:10.1016/j.clnu.2017.11.021

Cited by 72 publications

(88 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, many of the patients took medication for diabetes; thus, there is a possibility that the results of insulin sensitivity were not accurate. Fourth, whether cut-off of low muscle mass of a weight-adjusted SMI <37.0% for males and <28.0% for females [12], which is based on the data of people with Western, is applicable to this study population is unclear. However, this cut-off was used for Korean people previously [12].…”

Section: Discussionmentioning

confidence: 97%

“…Moreover, we determined the cut-off levels of Cre/BW and Cre/(CysC × BW) for low muscle mass in both males and females. The Cre/(CysC × BW) is a good marker for low muscle mass especially when the patients gain weight due to an increase of fat mass, even though they lose muscle mass [12]. Thus, the patients with a Cre/(CysC × BW) under 0.0145 for males and 0.0090 for females are at risk of low muscle mass and further metabolic related disease.…”

Section: Discussionmentioning

confidence: 99%

“…The height-adjusted SMI was calculated as follows: height-adjusted SMI = (appendicular muscle mass in kg)/(height in m 2 ) [7]. The weight-adjusted SMI was calculated as follows: weight-adjusted SMI = ([absolute muscle mass in kg]/[BW in kg]) × 100 [12]. The cut-off of low muscle mass was defined as a weight-adjusted SMI <37.0% for males and <28.0% for females [12].…”

Section: Data Collection and Measurementsmentioning

confidence: 99%

“…The weight-adjusted SMI was calculated as follows: weight-adjusted SMI = ([absolute muscle mass in kg]/[BW in kg]) × 100 [12]. The cut-off of low muscle mass was defined as a weight-adjusted SMI <37.0% for males and <28.0% for females [12].…”

Section: Data Collection and Measurementsmentioning

confidence: 99%

“…fatty liver disease (NAFLD) [9][10][11][12] and nonalcoholic steatohepatitis (NASH) [13][14][15]. In addition, it has been reported that weight-adjusted SMI is associated with insulin sensitivity [16].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

et al. 2020

View full text Add to dashboard Cite

We have previously reported that the creatinine (Cre) to cystatin C (CysC) ratio is associated with height-adjusted skeletal muscle mass index (SMI). However, weight-adjusted SMI is reported to be a more useful marker of insulin sensitivity than height-adjusted SMI. Thus, we hypothesized that the creatinine to (cystatin C × body weight [BW]) relationship (Cre/ [CysC × BW]) might be associated with weight-adjusted SMI. In this cross-sectional study of 169 males and 132 females, a body composition analyzer was used and the weight-adjusted SMI was calculated as (absolute muscle mass [kg]/BW [kg]) × 100. The cut-off of low muscle mass was defined as weight-adjusted SMI <37.0% for males and <28.0% for females. The Cre/(CysC × BW) was correlated with weight-adjusted SMI in both males (r = 0.484, p < 0.001) and females (r = 0.538, p < 0.001). In addition, Cre/(CysC × BW) was associated with weight-adjusted SMI in both males (standardized β = 0.493, p < 0.001) and females (standardized β = 0.570, p < 0.001) after adjusting for covariates. According to the receiver operator characteristic (ROC) curve analysis, the optimal cut-off point of Cre/(CysC × BW) for low muscle mass was 0.0145 (area under the ROC curve [AUC] 0.756 [95% confidence interval {95% CI} 0.644-0.842], sensitivity = 0.96, specificity = 0.47, p < 0.001) in males and 0.0090 (AUC 0.976 [95% CI 0.894-0.995], sensitivity = 1.00, specificity = 0.93, p < 0.001) in females. There is a correlation between Cre/(CysC × BW) and weight-adjusted SMI. The Cre/(CysC × BW) could be a practical screening marker for low muscle mass.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Data Collection and Measurementsmentioning

confidence: 99%

Section: Data Collection and Measurementsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

et al. 2020

View full text Add to dashboard Cite

show abstract

Role of Sarcopenia in Nonalcoholic Fatty Liver Disease: Definition Is Crucially Important

Peng

2018

Hepatology

Self Cite

View full text Add to dashboard Cite

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models

Nachit

Rudder²,

Thissen³

et al. 2020

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Non‐alcoholic fatty liver (NAFL) disease (NAFLD) is the most common chronic liver disease in the world. While most subjects have ‘inert’ NAFL, a subset will progress to non‐alcoholic steatohepatitis (NASH) and its life‐threatening complications. A substantial body of literature supports that a low muscle mass, low strength, and/or muscle fatty infiltration (myosteatosis) are associated with NAFLD severity. Here, we evaluated the muscle compartment in NASH preclinical models to decipher the kinetics of muscle alterations in relation with liver disease progression. Methods We developed and validated a micro‐computed tomography‐based methodology to prospectively study skeletal muscle mass and density in muscle and liver (i.e. reflecting fatty infiltration) in a high‐throughput and non‐invasive manner in three preclinical NAFLD/NASH rodent models: fat aussie (FOZ) mice fed a high‐fat diet (FOZ HF), wild‐type (WT) mice fed a high‐fat high‐fructose diet (WT HFF), and WT mice fed a high‐fat diet (WT HF). We compared them with WT mice fed a normal diet (WT ND) used as controls. Results ‐FOZ HF with fibrosing NASH had sarcopenia characterized by a reduced muscle strength when compared with WT HF and WT HFF with early NASH and WT ND controls (165.2 ± 5.2 g vs. 237.4 ± 11.7 g, 256 ± 5.7 g, and 242.9 ± 9.3 g, respectively, P 60; 0.001). Muscle mass or strength was not lower in FOZ HF, WT HF, and WT HFF with early NASH than in controls. Myosteatosis was present in FOZ HF with fibrosing NASH, but also in FOZ HF, WT HF, and WT HFF with early NASH (muscle density = 0.50 ± 0.02, 0.62 ± 0.02, 0.70 ± 0.05, and 0.75 ± 0.03, respectively, with P 60; 0.001 when compared with respective controls). Myosteatosis degree was strongly correlated with NAFLD activity score (r = −0.87, n = 67, P 60; 0.001). In multivariate analysis, the association between myosteatosis and NASH was independent from homeostatic model assessment of insulin resistance and visceral fat area (P 60; 0.05). Myosteatosis degree powerfully discriminated NASH from benign NAFL and normal liver (area under the receiver operating characteristic = 0.96, n = 67, P 60; 0.001). Conclusions Taken together, our data support that there is no sarcopenia in obese mice with early NASH. In contrast, the severity of myosteatosis reflects on hepatocellular damage and inflammation during early NASH development. This observation prompts us to exploit myosteatosis as a novel non‐invasive marker of NASH.

show abstract

Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition

Cited by 72 publications

References 29 publications

Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

Role of Sarcopenia in Nonalcoholic Fatty Liver Disease: Definition Is Crucially Important

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models

Contact Info

Product

Resources

About